Table 2.
Variables (n = 563) | |
---|---|
Treatment characteristics | |
Re-excision (no. of operations) | |
0 | 502 (89.2%) |
1 | 60 (10.7%) |
2 | 1 (0.2%) |
Margin achieved | |
< 1 mm | 8(1.4%) |
1–2 mm | 22 (3.9%) |
3–4 mm | 67(11.9%) |
≥ 5 mm | 461 (81.9%) |
Unknown | 5 (0.9%) |
Radiation boost | |
Yes | 340 (60.4%) |
No | 223 (39.6%) |
Chemotherapy | |
Yes | 114(20.2%) |
No | 442 (78.5%) |
Unknown | 7(1.2%) |
Hormonal therapy | |
Yes | 442 (78.5%) |
No | 85 (15.1%) |
Unknown | 36 (6.4%) |
Clinical outcomes | |
Follow-up: median (range) | 4.8 (0.08–8.3) yrs |
5-year actuarial IBTR rate | 1.1% |
5-year crude IBTR rate | 0.9% (5 of 563) |
5-year actuarial DDR rate | 5.4% |
5-year crude DDR rate | 5.2% (29 of 563) |
5-year breast cancer specific survival | 95.0% |
5-year breast cancer specific survival by NPI groups | |
Group 1 (excellent prognostic group) | 100% |
Group 2 (good) | 99.2% |
Group 3 (moderate I) | 96.1% |
Group 4 (moderate II) | 86.6% |
Group 5 (poor) | 88.6% |
Group 6 (very poor) | 75.2% |
Overall 5-year survival | 90.3% |
IBTR, ipsilateral breast tumour recurrence; DDR, distant disease recurrence; NPI, Nottingham Prognostic Index.